Project Grant R01HL174310
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$602K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $5,154,906.00 in funding to Versiti Wisconsin, Inc. to conduct a multi-disciplinary investigation of the molecular mechanisms underlying clinically important immune-mediated thrombocytopenic and thrombotic disorders. The research program, which involves collaboration with the Children's Hospital of Philadelphia, focuses on examining the...
This Project Grant award for $2,600,114 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to evaluate the role of thiol isomerases (TIs) and oxidant stress in thrombus (blood clot) formation. The key research objectives are to: Determine how oxidants generated in disease states promote specific cysteine modifications in the TI protein disulfide isomerase (PDI), and how these oxidative changes to PDI...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,340,904 to the University of Virginia to investigate the role of interleukin-13 (IL-13) and hyaluronan (HA) in the pathology of COVID-19. The 4-year project, beginning August 2024, aims to determine how IL-13 induces HA matrices in the lungs during SARS-CoV-2 infection and how this leads to inflammation and respiratory...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $395,314.00 to The Leland Stanford Junior University to define the innate immune cell profile involved in the development of inhibitory antibodies against infused coagulation protein factor VIII (FVIII) in persons with hemophilia A. The research aims to 1) characterize the cytokine microenvironment and CD4+ T cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support a series of experiments to investigate the role of fibrinogen as a pathologic and targetable mediator of COVID-19-associated coagulopathy. The $391,250 in funding will allow the researchers at Emory University to define the impact of therapeutic plasma exchange on blood rheology and vascular integrity in COVID-19 patients, as well...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $503,637 to The University of Kentucky Research Foundation to conduct research on the mechanisms of thrombosis (blood clotting) in patients with SARS-CoV-2 infection, the virus that causes COVID-19. The research aims to investigate how COVID-19 leads to the formation of microclots, which can cause localized tissue damage, as well as the...
This $1,779,777 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the role of the GAB2-MALT1 signaling pathway in endothelial cells and its contribution to venous thrombosis. The research aims to: 1) Determine the molecular mechanisms by which GAB2 mediates thromboinflammatory signaling in endothelial cells, 2) Investigate the role of endothelial GAB2-MALT1 signaling in...
This $666,710 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize the role of the BCL6 co-repressor (BCOR) gene in regulating coagulation factor VII and venous thromboembolism (VTE) risk. The grant's key objectives are to: 1) Determine how BCOR suppresses factor VII expression in hepatocytes through epigenetic regulators PRC1.1 and ATAC; 2) Investigate how a...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $813,042 to President and Fellows of Harvard College (Harvard Medical School) to develop an innovative causal artificial intelligence (AI) approach for mitigating hematologic adverse events in patients with myeloid malignancies. The project aims to (1) integrate clinical, laboratory, and pathology data to identify key...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to investigate the role of fibrinogen in regulating thromboinflammation in acute and chronic venous thrombosis. The $151,523 award, with a period of performance from January 1, 2025 to December 31, 2029, will support the use of novel RNA therapy to selectively reduce circulating fibrinogen levels in preclinical rodent and...